deCODE genetics (DCGN) Receives Reinstatement Notice From NASDAQ
More News related to DCGN
- deCODE genetics, Inc. Files Voluntary Chapter 11 Petition to Facilitate Sale of Assets
- After-Hours Movers 9/17: IHS, GEOY Higher; CLUB, FSP, NMM, SIRI Lower
- deCODE genetics (DCGN) Receives Non-Compliance Notification
- deCODE genetics (DCGN) Discovers Second Common Genetic Risk Factor for Atrial Fibrillation and Stroke
- Morning Movers 6/30: PHC, VICL, GERN, LEA, XCO Higher; RZ, SRZ, DCGN, SCHN Lower
deCODE genetics (Nasdaq: DCGN) has received notice from the the Nasdaq Hearing and Listing Review Council that the listing of the company's common stock will be reinstated to the Nasdaq Global Market effective from the opening of trading on Monday, June 29. deCODE's common stock will continue to trade under the symbol DCGN.
The reinstatement follows the Listing Council's reversal of a decision in February by the Nasdaq Listing Qualifications Panel under which the listing of deCODE's common stock was transferred to the Nasdaq Capital Market.
deCODE is a bio-pharmaceutical company developing drugs and DNA-based tests to improve the treatment, diagnosis and prevention of common diseases.[SM]
Related Categories
Corporate NewsStocks Mentioned
+0.01Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
